Dermatology and therapy · 2026
Treatment Patterns and Health-Related Quality of Life in Patients with Alopecia Areata Stratified by Disease Severity in the USA.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mostaghimi Arash, Soliman Ahmed M, Richter Sven G, Austin Jenny, Russnak Alexa
Аннотация
INTRODUCTION: Alopecia areata (AA) is an inflammatory hair loss disorder, which negatively impacts health-related quality of life (HRQoL). This study investigates treatment patterns and HRQoL by AA disease severity.
METHODS: Data were drawn from the Adelphi Real World AA Disease Specific Programme™, a cross-sectional survey of dermatologists and patients in the USA from November 2023 to June 2024. Dermatologists reported patient demographics, clinical characteristics, treatment patterns, and mental health. Patients completed AA Symptom Impact Scale, Skindex-16 AA, and Work Productivity and Activity Impact questionnaires. Data were stratified by AA-Investigator Global Assessment (IGA) scores and physician-assessed disease severity.
RESULTS: Overall, 65 physicians reported on 501 patients, of whom 81 self-reported data. In total, 211 patients had severe/very severe AA-IGA-scored AA, of whom 66% received oral Janus kinase and 31% received non-topical corticosteroids. Among 501 patients, 43% had concomitant conditions. Anxiety (74%) and depression (61%) were most prevalent in severe/very severe AA-IGA-scored AA. Patients with severe/very severe AA reported notably high mean (standard deviation) scores on the global AA Symptom Impact Scale (AA-IGA, 3.1 [2.5]; physician-assessed, 3.0 [2.4]), Skindex-16 Emotion subscale (AA-IGA, 59.5 [29.8]; physician-assessed, 59.8 [27.5]) and overall work impairment (AA-IGA, 16.2% [21.4]; physician-assessed, 17.5% [20.2]).
CONCLUSIONS: This study showed that AA severity may correlate with HRQoL, highlighting the need for validated severity measures.
METHODS: Data were drawn from the Adelphi Real World AA Disease Specific Programme™, a cross-sectional survey of dermatologists and patients in the USA from November 2023 to June 2024. Dermatologists reported patient demographics, clinical characteristics, treatment patterns, and mental health. Patients completed AA Symptom Impact Scale, Skindex-16 AA, and Work Productivity and Activity Impact questionnaires. Data were stratified by AA-Investigator Global Assessment (IGA) scores and physician-assessed disease severity.
RESULTS: Overall, 65 physicians reported on 501 patients, of whom 81 self-reported data. In total, 211 patients had severe/very severe AA-IGA-scored AA, of whom 66% received oral Janus kinase and 31% received non-topical corticosteroids. Among 501 patients, 43% had concomitant conditions. Anxiety (74%) and depression (61%) were most prevalent in severe/very severe AA-IGA-scored AA. Patients with severe/very severe AA reported notably high mean (standard deviation) scores on the global AA Symptom Impact Scale (AA-IGA, 3.1 [2.5]; physician-assessed, 3.0 [2.4]), Skindex-16 Emotion subscale (AA-IGA, 59.5 [29.8]; physician-assessed, 59.8 [27.5]) and overall work impairment (AA-IGA, 16.2% [21.4]; physician-assessed, 17.5% [20.2]).
CONCLUSIONS: This study showed that AA severity may correlate with HRQoL, highlighting the need for validated severity measures.